Acceleration of the Thrombin Inactivation of Single Chain Urokinase-type Plasminogen Activator (Pro-urokinase) by Thrombomodulin

Gerard A. W. de Munk, Eleonore Groeneveld, and Dingeman C. Rijken
Gaubius Institute TNO, Leiden, The Netherlands

Abstract
The in vitro effects of thrombomodulin on the inactivation of single chain urokinase-type plasminogen activator (scu-PA) by thrombin were investigated by incubating scu-PA with varying concentrations of human thrombin, in both the absence and presence of soluble rabbit thrombomodulin. 50% inactivation of scu-PA occurred in 45 min at 160 ng/ml thrombin in the absence of thrombomodulin and at 4.6 ng/ml thrombin in the presence of thrombomodulin. No difference was found in either the absence or the presence of thrombomodulin between the inactivation rates of high molecular weight scu-PA, and a low molecular weight scu-PA which lacked the growth factor and kringle domains. Enzyme kinetic experiments with varying concentrations of scu-PA showed that thrombomodulin decreased the $K_m$ of thrombin for scu-PA from 7.8 to 0.43 $\mu$M and increased the $k_{cat}$ from 0.30 to 1.2 s$^{-1}$, corresponding to a 70-fold increase in the second-order rate constant $k_{cat}/K_m$. SDS-polyacrylamide gel electrophoresis showed that scu-PA was cleaved into two chains upon inactivation by thrombin, and confirmed the acceleration effect of thrombomodulin on inactivation of scu-PA. Thrombomodulin thus not only has anticoagulant properties but is also antifibrinolytic. The acceleration may imply a new mechanism for the regulation of local plasminogen activator activity on the cell surface. (J. Clin. Invest. 1991. 88:1680–1684.) Key words: fibrinolysis • thrombolytic therapy • endothelial cells • protein C • fetomodulin

Introduction
Single chain urokinase-type plasminogen activator (scu-PA), also called pro-urokinase, is the precursor of active two-chain urokinase-type plasminogen activator (tcu-PA), a serine protease that activates plasminogen to plasmin (for reviews, see 1–3). Although both forms of urokinase-type plasminogen activator (u-PA) are successfully applied for fibrinolytic therapy, it is not yet known whether u-PA plays an important role in endogenous fibrinolysis. On the other hand, scu-PA probably does play a role in cell migration, tissue destruction and tissue remodeling (for review, see 4). Both scu-PA and tcu-PA have $\sim 50,000$ $M_\text{f}$; tcu-PA consists of two chains with $M_\text{f}$ 20,000 and 30,000, held together by a disulfide bridge (5). In certain cell cultures a low molecular weight (LMW) form of scu-PA with $M_\text{f}$ 32,000 occurs (6, 7) that lacks the NH$_2$-terminal part (the epidermal growth factor domain and the kringle domain) of the high molecular weight (HMW) form of scu-PA. No significant difference has yet been found between the thrombolytic properties of LMW scu-PA and HMW scu-PA (8, 9).

The single chain form of u-PA can be converted to active tcu-PA by hydrolysis of the Lys 158-Ile 159 peptide bond by plasmin (10), plasma kallikrein (11, 12), Factor XII (11), and trypsin (13). Thrombin hydrolyses scu-PA at the Arg 156-Phe 157 bond, leading to an inactive tcu-PA (11, 14, 15), which is much less sensitive to activation with plasmin (16).

Thrombomodulin is a membrane protein of endothelial cells, which forms a 1:1 complex with thrombin (17) and stimulates the anticoagulant properties of thrombin by accelerating the activation of protein C (18), (for reviews, see 19–22). The aims of this study were to investigate the effect of thrombomodulin on the inactivation of scu-PA by thrombin and to compare the inactivation by thrombin of HMW and LMW scu-PA. We found that thrombomodulin strongly accelerated the inactivation of both HMW and LMW scu-PA by thrombin.

Methods
Materials. Both HMW scu-PA and LMW scu-PA, purified from human embryonic kidney cell cultures (23), were donated by Dr J. Henkin, Abbott Laboratories (Abbott Park, IL). Rabbit lung thrombomodulin and goat anti-rabbit thrombomodulin IgG were purchased from American Diagnostica Inc. (Greenwich, CT). Hirudin was from Pentapharm (Basel, Switzerland). Goat non-immune IgG was isolated by two sodium sulfate precipitations (24). Human plasmin and chromogenic substrate Pyro-Glu-Gly-Arg-pNA (S-2444) were from Kabi AB (Stockholm, Sweden). Aprotinin was from Bayer AG (Leverkusen-Bayerwerk, Germany). Human thrombin (T 6759) and BSA (A 7030) were purchased from Sigma Chemical Co. (St. Louis, MO). A specific activity of 3.3 NIH U/µg (as indicated by the manufacturer) was used for the calculation of concentrations.

Assay of scu-PA. The activity of scu-PA was determined by measuring the latent amidolytic activity with S-2444 as follows: scu-PA was diluted with 20 mM Tris/HCl pH 7.5, 100 mM NaCl, 3 mM CaCl$_2$, 0.1% Tween 80, 0.1% BSA, 0.2 U/ml hirudin (or more, depending on the amount of thrombin present in the solution) to a concentration of 60–1,000 ng/ml and plasmin was added (final concentration 0.1 CU/ml). After 20 min activation at 37°C, the amidolytic activity of 75 µl activated scu-PA solution was measured by adding 175 µl 0.43 mM S-2444 in 50 mM Tris/HCl, 38 mM NaCl, 0.01% Tween 80, and 20 KIU/ml aprotinin, pH 8.8. The increase of the optical density at 405
nm was measured during incubation at 37°C by using a Titertek multiskan (Etabl Oy, Finland).

Complexation of thrombin with thrombomodulin. Various concentrations of thrombin up to 0.30 μg/ml (8.1 nM) were incubated with 1.0 μg/ml thrombomodulin (13.5 nM) for 5 min at 37°C immediately before each experiment. Functional activity of the thrombomodulin preparation was demonstrated by inhibition of the fibrinogen-clotting activity of thrombin by thrombomodulin, as described by Esmon et al. (17).

Inactivation of scu-PA. The principle of the assay for scu-PA inactivation was described (15). During 45 min at 37°C, 240 ng/ml HMW or LMW scu-PA was incubated with 0–0.6 μg/ml thrombin or with 0.0–0.5 μg/ml thrombin after pre-incubation with 1 μg/ml thrombomodulin, in 20 mM Tris/HCl, pH 7.5, 100 mM NaCl, 3 mM CaCl₂, 0.1% BSA, and 0.1% Tween 80. The inactivation was stopped by diluting the mixture in cold hirudin-containing dilution buffer of the assay for scu-PA. In another experiment, varying concentrations of thrombomodulin (0–1 μg/ml) were pre-incubated with 15 ng/ml thrombin before 240 ng/ml HMW scu-PA was added. After 45 min at 37°C, the inactivation was stopped and remaining scu-PA was assayed.

Goat anti-rabbit thrombomodulin IgG (40 μg/ml) or goat non-immune IgG (40 μg/ml) was incubated at 37°C for 5 min with 50 ng/ml thrombomodulin. After thrombin was added (15 ng/ml final concentration) and incubated again at 37°C for 5 min, HMW scu-PA (240 ng/ml final concentration) was added and incubated at 37°C for 45 min. Remaining scu-PA was measured.

The effect of Ca²⁺ on the inactivation of 240 ng/ml HMW scu-PA was studied by adding 0–0.60 μg/ml thrombin alone, or 0–0.12 μg/ml thrombin after incubation with 1 μg/ml thrombomodulin, both in the presence and in the absence of 3 mM CaCl₂. After incubation at 37°C for 45 min, remaining scu-PA was assayed.

Kinetic experiments. Concentrations of HMW scu-PA ranging from 0.05 to 4 μg/ml were incubated with 4 nM (150 ng/ml) thrombin or 0.04 nM (1.5 ng/ml) thrombin after pre-incubation with 1 μg/ml thrombomodulin in 20 mM Tris/HCl, pH 7.5, 100 mM NaCl, 3 mM CaCl₂, 0.1% Tween 80, and 0.1% BSA at 37°C. At intervals of 0, 15, 30, 45 and 60 min, aliquots were taken and the reaction was stopped as described above. Remaining scu-PA was measured with S-2444 after activation with plasmin. The 100% values were not affected by either the absence or presence of thrombomodulin.

SDS-polyacrylamide gel electrophoresis. SDS-PAGE was performed according to the method of Laemmli (25), using a 12% polyacrylamide gel. Samples of 30 μl were diluted 1:1 in sample buffer containing 4% (wt/vol) SDS, 20% (wt/vol) glycerol, 0.005% (wt/vol) bromophenol blue and 4% (wt/vol) 2-mercaptoethanol in 125 mM Tris/HCl, pH 6.8 and incubated for 5 min at 100°C. A calibration kit with standard proteins was obtained from Pharmacia LKB Biotechnology (Uppsala, Sweden).

Results

Inactivation of HMW and LMW scu-PA. To study the effect of thrombomodulin on the inactivation of scu-PA by thrombin, 240 ng/ml HMW and LMW scu-PA were incubated for 45 min at 37°C with varying amounts of thrombin, both in the absence and presence of 1 μg/ml thrombomodulin. Remaining scu-PA, not inactivated by thrombin, was activated with plasmin and quantified using S-2444. 50% of scu-PA was inactivated by 165±41 ng/ml (mean±SD, n = 5) thrombin in the absence of thrombomodulin or by only 4.6±1.4 (n = 4) ng/ml thrombin in the presence of thrombomodulin (Fig. 1). No difference was found in the relative inactivation rate between LMW scu-PA and HMW scu-PA, either in the absence or in the presence of thrombomodulin.

Fig. 2 shows that remaining scu-PA gradually decreased at increasing thrombomodulin concentrations and a fixed thrombin concentration of 15 ng/ml. To calculate the Kd for the thrombin-thrombomodulin complex from these data, the percentages of remaining scu-PA were converted into concentrations of the thrombin-thrombomodulin complex, by reference to the standard curve prepared with thrombin in the presence of 1 μg/ml thrombomodulin (Fig. 1) and by assuming that all thrombin had formed a 1:1 complex at 1 μg/ml thrombomodulin. The concentrations of free and bound thrombomodulin were calculated and plotted double reciprocally (Fig. 2, inset), resulting in an apparent Kd of 0.57 nM for the thrombin-thrombomodulin complex.
The neutralizing effect of goat antibodies against thrombomodulin was studied in Fig. 3. Approximately 4% scu-PA was inactivated by 15 ng/ml thrombin alone, whereas 56% was inactivated by the same concentration thrombin complexed with 50 ng/ml thrombomodulin. The antibodies almost completely quenched the accelerating effect of thrombomodulin on the inactivation of HMW scu-PA, whereas goat non-immune IgG had only a minor effect.

SDS-PAGE of inactivated HMW and LMW scu-PA. HMW and LMW scu-PA were incubated with a low concentration of thrombin (75 ng/ml), both with and without 1 μM thrombomodulin, or with a high concentration of thrombin (1.2 μM/ml), and subjected to SDS-PAGE (Fig. 4). The low concentration of thrombin partially cleaved HMW scu-PA into two subunits: one of M, 32,000 and one of M, 20,000 or 22,000 (lane 3). In contrast, the thrombin-thrombomodulin complex completely cleaved HMW scu-PA (lane 4), as did the high concentration of thrombin (lane 5). Comparison of the extent of cleavage in lanes 3 and 4 clearly shows the accelerating effect of thrombomodulin. As expected, inactivation of LMW scu-PA did not lead to a significant shift of the protein band, because a peptide of only 13 amino acids was supposed to be cut off.

Kinetics of the inactivation of HMW scu-PA. Varying amounts of HMW scu-PA were incubated with thrombin or with thrombin after preincubation with excess thrombomodulin. Kinetic analysis shows that the inactivation rate of scu-PA by both thrombin and the thrombin–thrombomodulin complex obeyed Michaelis-Menten kinetics. Using Lineweaver-Burk plots (Fig. 5), the K_m and k_cat were determined to be 7.8 μM and 0.39 s^{-1}, respectively, in the case of thrombin and 0.43 μM and 1.2 s^{-1}, respectively, for the thrombin–thrombomodulin complex (Table I). The second-order rate constant (k_cat/K_m) of thrombin increased from 0.039 to 2.7 μM^{-1}·s^{-1} (70 times) by complex formation with thrombomodulin.

Effect of Ca^{2+} on the inactivation of HMW scu-PA. In the presence of Ca^{2+} more thrombin was required to inactivate HMW scu-PA than in the absence of Ca^{2+}. This was observed both in the presence (23 times more thrombin to achieve 50% inactivation) and in the absence (9 times more) of thrombomodulin (Fig. 6). An experiment with varying Ca^{2+} concentrations (0–6 mM) revealed that under both conditions a plateau was reached at 3 mM Ca^{2+} (not shown).

Discussion

This study shows an accelerating effect of solubilized rabbit thrombomodulin on the inactivation of scu-PA by human thrombin. This finding was supported by the following observations: (a) The effect of thrombomodulin was dose dependent and corresponded with an apparent K_a for the thrombin-thrombomodulin complex of 0.57 nM, which is very similar to previously reported values of 0.48 and 0.54 nM (18, 29). (b) Goat anti-rabbit thrombomodulin IgG inhibited the accelerating effect of thrombomodulin. (c) The action of thrombomodulin accompanied the conversion of scu-PA into a tcu-PA that was indistinguishable on SDS-PAGE from the tcu-PA formed by a high concentration of thrombin.

The inactivation of HMW scu-PA by the thrombin–thrombomodulin complex as well as by thrombin alone obeyed Michaelis-Menten kinetics. The k_cat/K_m for thrombin alone was 0.039 μM^{-1}·s^{-1} and increased 70-fold to 2.7 μM^{-1}·s^{-1} for the thrombin-thrombomodulin complex. It is difficult to establish whether the latter rate constant is high enough to be significant in vivo. However, the rate constant is of the same order of magnitude as that for the activation of scu-PA by plasmin (30, 31). In addition, the k_cat/K_m for the activation of protein C by the thrombin–thrombomodulin complex in an assay system as used in this study is 0.81 μM^{-1}·s^{-1} (27), which is also of the same order of magnitude (Table I). The activation rate of protein C by the complex further increases on cell surfaces and in the presence of phospholipids (18, 28). It still has to be determined whether the inactivation rate of scu-PA on cell surfaces is higher than in the solubilized system.

In the absence of endothelial cells, Ca^{2+} reduces the rate of protein C activation by thrombin, but stimulates the activation rate by the thrombin–thrombomodulin complex (32). The thrombin–thrombomodulin interaction is Ca^{2+} independent (17). In contrast to the diverging effects of Ca^{2+} on protein C
activation, Ca²⁺ reduced the inactivation of scu-PA by both thrombin and thrombin–thrombomodulin complex. It is not yet clear whether the active site of thrombin is affected or whether the substrate scu-PA is changed by a hitherto unknown Ca²⁺-binding phenomenon.

The two molecular weight forms (HMW and LMW) of scu-PA were equally sensitive to inactivation by thrombin or the thrombin–thrombomodulin complex. LMW scu-PA, a potential thrombolytic agent, has, therefore, no advantage or disadvantage compared with HMW scu-PA in terms of sensitivity for inactivation in thrombolytic therapy.

The physiological importance of the acceleration of scu-PA inactivation by thrombomodulin may lie in the close regulation of local u-PA activity on surfaces of endothelial cells and other cells that express thrombomodulin. Through this mechanism thrombin and thrombomodulin may affect processes such as cell migration, tissue destruction and remodeling. In this respect, it is interesting to note that fetomodulin, a surface marker protein of fetal development, has recently been demonstrated to be identical to thrombomodulin (33). During embryonic development this marker is not only expressed in vasculatures but also in nonvascular tissues. Consequently, it has been suggested that thrombomodulin has another function, in addition to that of an anticoagulant (33). This study indicates such a function, implying the regulation of u-PA activity during embryonic development.

If scu-PA plays a role in endogenous fibrinolysis, thrombomodulin should be considered as a protein with antifibrinolytic properties in addition to its well-known anticoagulant properties. Both properties may be necessary, either simultaneously or successively, to regulate size and longevity of fibrin deposits. Inactivation of scu-PA by thrombomodulin-bound thrombin may also occur during thrombolytic therapy with scu-PA, the more so as thrombin seems to be formed in patients during thrombolysis (34). This would be an additional argument for administering thrombin inhibitors simultaneously with the thrombolytic agent scu-PA (35).

**Acknowledgments**

We thank Dr. J. Henkin and Dr. A. A. Sasahara, Abbott Laboratories, for generously providing HMW and LMW scu-PA.

This study was supported by the Netherlands Heart Foundation (grant 87.041 and Established Investigatorship of D. C. Rijken).

---

**Table I. Kinetic Parameters of the Inactivation of HMW Scu-PA by Thrombin and Thrombin–Thrombomodulin Complex (Derived from Fig. 5) and a Comparison with Literature Data for the Activation of Protein C**

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>Substrate</th>
<th>$K_m$</th>
<th>$k_{in}$</th>
<th>$k_{cat}/K_m$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$\mu M$</td>
<td>$s^{-1}$</td>
<td>$\mu M^{-1} \cdot s^{-1}$</td>
</tr>
<tr>
<td>Thrombin</td>
<td>scu-PA</td>
<td>7.8</td>
<td>0.30</td>
<td>0.039</td>
</tr>
<tr>
<td>Thrombin–thrombomodulin</td>
<td>scu-PA</td>
<td>0.43</td>
<td>1.2</td>
<td>2.7</td>
</tr>
<tr>
<td>Thrombin*</td>
<td>protein C</td>
<td>60</td>
<td>0.02</td>
<td>0.00033</td>
</tr>
<tr>
<td>Thrombin–thrombomodulin</td>
<td>protein C</td>
<td>7.6</td>
<td>6.2</td>
<td>0.81</td>
</tr>
</tbody>
</table>

* According to ref. 27; † according to ref. 28.
References


